| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/15-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | RAL |
| WB Predicted band size | 24 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human RALA |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于RALA抗体的模拟参考文献示例(内容基于常见研究主题构造，非真实文献)：
---
1. **文献名称**：*"Development and Validation of a Novel RALA-Specific Monoclonal Antibody for Cancer Research"*
**作者**：Li X, Chen Y, Wang J, et al.
**摘要**：本研究报道了一种高特异性抗RALA单克隆抗体的开发，通过免疫印迹和免疫荧光验证其在多种癌细胞系中的检测效果。实验表明该抗体能有效区分RALA与其同源蛋白RALB，并证实RALA在乳腺癌细胞迁移中起关键作用。
---
2. **文献名称**：*"RALA GTPase Regulates Autophagosome Formation through Antibody-Based Proteomic Screening"*
**作者**：Martinez R, Kim DH, Suzuki K.
**摘要**：通过基于抗体的蛋白质组学筛选，作者发现RALA参与自噬体形成的早期阶段。使用特异性RALA抗体敲低实验显示，RALA缺失导致LC3-II积累受阻，提示其在自噬通路中具有调控功能。
---
3. **文献名称**：*"Dysregulation of RALA Expression in Neurodegenerative Disorders: Evidence from Immunohistochemical Analysis"*
**作者**：Garcia SM, Thompson AA, O'Connor T.
**摘要**：利用商业化RALA抗体对阿尔茨海默病脑组织进行免疫组化分析，发现RALA在神经元突触区域的表达显著降低，提示其异常可能与tau蛋白病理相关，为神经退行性病变机制研究提供了新方向。
---
**注**：以上文献为示例性内容，实际研究中请通过PubMed或Google Scholar检索真实文献。
RALA (RAS-like proto-oncogene A) is a member of the RAL subfamily within the RAS superfamily of small GTPases, which play pivotal roles in regulating intracellular signaling pathways. Discovered in the 1980s, RALA cycles between an inactive GDP-bound state and an active GTP-bound state, controlled by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). It is implicated in diverse cellular processes, including vesicle trafficking, cytoskeletal reorganization, and cell proliferation, often interacting with effectors like exocyst complex subunits (EXOC) and RAL-binding protein 1 (RALBP1). Dysregulation of RALA signaling is linked to cancer progression, metastasis, and therapy resistance, particularly in tumors with RAS mutations, where RALA serves as a critical downstream effector.
RALA-specific antibodies are essential tools for studying its expression, localization, and activation status in physiological and pathological contexts. These antibodies enable detection of RALA isoforms (RALA and RALB) and post-translational modifications (e.g., phosphorylation) via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Recent research highlights RALA's potential as a therapeutic target, driving interest in antibodies for diagnostic applications or to validate RALA inhibition in preclinical models. Despite progress, challenges remain in distinguishing RALA's isoform-specific functions and developing isoform-selective inhibitors, underscoring the continued importance of high-quality RALA antibodies in both basic and translational research.
×
